Dendritic Cell-Targeting Universal Vaccine for Influenza Infection
AssigneeUniversity of Manitoba
InventorXiao-Jian Yao
Life of this patent
Estimating the term…
Abstract
We have recently developed a novel DC-targeting vaccine platform using Ebola glycoprotein (EboGP) DC-targeting domain-based fusion protein technology. Here, we will use this technology to generate universal vaccines against Influenza A by fusing a DC-targeting/activation domain (EboGPAM), derived from EboGP to I) a tetrameric conserved extracellular domain of M2 (M2e) of Influenza A strains from human, birds, and swine; 2) the conserved stalk regions (HAcs) of HA and an M2 polypeptide from H5N1 strain; and 3) the HA head regions polypeptides (HAH5-1-3) derived from H5N1, H1 N1 and H3N2 strains.
Claims25
A fusion protein comprising an influenza virus surface protein peptide inserted in the mucin-like domain of a Filoviridae Virus glycoprotein wherein the influenza virus surface protein is selected from the group consisting of hemagglutinin and matrix-2 and the influenza virus surface protein peptide comprises 6 or more consecutive amino acids of the influenza virus surface protein.
(canceled)
(canceled)
A method of targeting an influenza virus surface protein peptide to a dendritic cell comprising:
- providing virus-like particles comprising as glycoprotein a Filoviridae Virus glycoprotein fusion protein comprising an influenza virus surface protein peptide inserted in the mucin-like domain of the Filoviridae Virus glycoprotein wherein the influenza virus surface protein is selected from the group consisting of hemagglutinin and matrix-2 and the influenza virus surface protein peptide comprises 6 or more consecutive amino acids of the influenza virus surface protein;
- and
- immunizing an individual with the virus-like particles.
A method of eliciting an immune response against an influenza surface protein peptide in an individual comprising:
- providing virus-like particles comprising as glycoprotein a Filoviridae Virus glycoprotein fusion protein comprising an influenza virus surface protein peptide inserted in the mucin-like domain of the Filoviridae Virus glycoprotein wherein the influenza virus surface protein is selected from the group consisting of hemagglutinin and matrix-2 and the influenza virus surface protein peptide comprises 6 or more consecutive amino acids of the influenza virus surface protein;
- and
- immunizing an individual in need of immunization against influenza virus with an effective amount of the virus-like particles.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.